Recruiting PHASE2 Cocaine Use Disorder

New treatment option for Cocaine Use Disorder

Official title Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction

ClinicalTrials.gov ID: NCT06125054

What this study is testing

What is Ketamine?

Ketamine is an investigational medicine, being studied as a potential treatment for cocaine use disorder.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The goal of this clinical trial is to learn about the effects of the combination of ketamine and realtime functional magnetic resonance imaging (fMRI) neurofeedback training in individuals with cocaine use disorder. The main questions the investigators aim to answer are: Can the investigators observe a positive, significant effect on percentage of cocaine use days of both interventions combined as well as stand alone interventions?
  • Phase 2: a mid-size study of how well it works
  • You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 55

You may be able to join if

  • Informed Consent as documented by signature
  • Male and female cocaine users 18 to 55 years of age
  • diagnostic and statisical manual (DSM)-5 diagnosis of CUD
  • Willingness to comply with the study protocol as explained by investigator
  • Normal level of language comprehension (German or Swiss-German)

You likely can't join if

  • Current or lifetime psychotic disorders
  • History of severe substance-induced psychosis
  • Current or lifetime bipolar I or II disorders
  • Current suicidality
  • Previous suicide attempts during the last 2 years
  • Current severe alcohol use disorder
See the full eligibility criteria
Who can join
  • Informed Consent as documented by signature
  • Male and female cocaine users 18 to 55 years of age
  • diagnostic and statisical manual (DSM)-5 diagnosis of CUD
  • Willingness to comply with the study protocol as explained by investigator
  • Normal level of language comprehension (German or Swiss-German)
What rules you out
  • Current or lifetime psychotic disorders
  • History of severe substance-induced psychosis
  • Current or lifetime bipolar I or II disorders
  • Current suicidality
  • Previous suicide attempts during the last 2 years
  • Current severe alcohol use disorder
  • Current severe cannabis use disorder
  • Current moderate or severe stimulant use disorder (other than cocaine)
  • Current moderate or severe benzodiazepine use disorder
  • Current opioid use disorder
  • First-degree relatives with psychotic disorders
  • Beck Depression Inventory Score greater than 25
  • Unmedicated or unstable hypertension
  • Severe illness (e. g. myocardial ischemia or arrythmias, severe pulmonary secretions, glaucoma, congestive heart failure or angina, significant renal or hepatic impairment)
  • Acute infection (e. g. pulmonary or upper respiratory tract infection)
  • Insufficient treated or uncorrected hyperthyroidism
  • Severe central nervous system related traumas or disorders (e. g. stroke, cerebral trauma with loss of consciousness over more than 24h, epilepsy)
  • Increased intracranial pressure
  • Medication directly affecting glutamate signaling (e. g. anticonvulsant medication)
  • Any unstable psychoactive medication (no changes in compounds within last 4 weeks before start of study)
  • Pregnancy or lactation
  • Women of childbearing potential with no use of medically accepted contraceptive (e. g. condoms, contraceptive diaphragm, birth control pill, hormone injection, intrauterine device)
  • BMI\>35
  • Allergy, hypersensitivity, or other adverse reaction to previous use of ketamine
  • Contradictions to magnetic resonance imaging
  • Concurrent participation in other clinical study

The study team makes the final eligibility decision.

Where it's taking place

  • Zurich, Canton of Zurich, Switzerland

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Zurich, Canton of Zurich, Switzerland. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.